Skip to main content
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2009 Nov 19;23(6):404–407. doi: 10.1002/jcla.20351

Prevalence characterization of extended‐spectrum β‐lactamases among Escherichia coli isolates collected in Zhengzhou

Zhijian Zhang 1, Xiaobing Guo 2, Qinxian Zhang 3,
PMCID: PMC6649103  PMID: 19927355

Abstract

Objectives: To determine the prevalence and the diversity of extended‐spectrum β‐lactamases (ESBLs) among Escherichia coli isolates in Zhengzhou, China.

Methods: Clinical isolates were collected and investigated from the first affiliated hospital of Zhengzhou University and its associated health‐care facilities in Zhengzhou, China, during the period from January 2006 to June 2008. Antibiograms were performed on Mueller–Hinton agar plates with the disc‐diffusion method and MICs were determined by the agar‐dilution method. Total DNA was extracted with a Qiagen mini kit and screened by PCR.

Results: Of 94 nonduplicate ESBL‐positive isolates, TEM‐type was encoded in 74 and 79% of the ESBL isolates. Fifty‐six isolates were SHV type ESBLs. CTX‐M‐1, CTX‐M‐14, CTX‐M‐25, and CTX‐M‐38 types were encoded in 30, 54, 6, and 4, respectively. OXA‐1‐type β‐lactamases were encoded in six and OXA‐20‐type was encoded in two isolates.

Conclusions: We describe a complex ESBL epidemiology. The study revealed a high rate of ESBL‐producing E. coli isolates. TEM and CTX‐M enzymes dominated in ESBL‐positive E. coli isolates in Zhengzhou, China. J. Clin. Lab. Anal. 23:404–407, 2009. © 2009 Wiley‐Liss, Inc.

Keywords: prevalence, extended‐spectrum β‐lactamases (ESBLs), Escherichia coli, Zhengzhou

REFERENCES

  • 1. Katherine J, Wilson GLK, Phiri A, Corkill JE, French N, Hart CA. Identification and characterization of ceftriaxone resistance and extended‐spectrum β‐lactamases in Malawian bacteraemic Enterobacteriaceae. J Antimicrob Chemother 2006;57:661–665. [DOI] [PubMed] [Google Scholar]
  • 2. Bonnet R, Dutour C, Sampaio JLM, et al. Novel cefotaximase (CTX‐M‐16) with increased catalytic efficiency due to substitution Asp‐240→Gly. Antimicrob Agents Chemother 2001;45:2269–2275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Cao V, Lambert T, Nhu DQ, et al. Distribution of extended‐spectrum β‐lactamases in clinical isolates of Enterobacteriaceae in Vietnam. Antimicrob Agents Chemother 2002;46:3739–3743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Casin I, Hanau‐Berçot I, Podglajen H, et al. Salmonella enterica serovar Typhimurium bla PER‐1‐carrying plasmid pSTI1 encodes an extended‐spectrum aminoglycoside 6'‐N‐acetyltransferase of type Ib. Antimicrob Agents Chemother 2003;47:697–703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. De Champs C, Poirel L, Bonnet R, et al. Prospective survey of β‐lactamases produced by ceftazidime‐resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 2002;46:3031–3034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. De Champs C, Sirot D, Chanal C, et al. A 1998 survey of extended‐spectrum β‐lactamases in Enterobacteriaceae in France. Antimicrob Agents Chemother 2002;44:3177–3179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Gniadkowski M, Schneider I, Palucha A, et al. Cefotaxime‐resistant Enterobacteriaceae isolates from a hospital in Warsaw, Poland: Identification of a new CTX‐M‐3 cefotaxime‐hydrolyzing β‐lactamase that is closely related to the CTX‐M‐1/MEN‐1 enzyme. Antimicrob Agents Chemother 1998;42:827–832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Vahaboglu H, Öztürk R, Aygün G, et al. Widespread detection of PER‐1‐type extended‐spectrum β‐lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: A nationwide multicentre study. Antimicrob Agents Chemother 1997;41:2265–2269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Girlich D, Poirel L, Leelaporn A, et al. Molecular epidemiology of the integron‐located VEB‐1 extended‐spectrum β‐lactamase in nosocomial enterobacterial isolates in Bangkok, Thailand. J Clin Microbiol 2001;l39:175–182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. De Champs C, Chanal C, Sirot D, et al. Frequency and diversity of class A extended‐spectrum β‐lactamases in hospitals of the Auvergne, France: A 2 year prospective study. J Antimicrob Chemother 2004;54:634–639. [DOI] [PubMed] [Google Scholar]
  • 11. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended‐spectrum β‐lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;32:S94–S103. [DOI] [PubMed] [Google Scholar]
  • 12. Woodford N, Ward ME, Kaufmann ME, et al. Community and hospital spread of Escherichia coli producing CTX‐M extended‐spectrum beta‐lactamases in the UK. J Antimicrob Chemother 2004;54:735–743. [DOI] [PubMed] [Google Scholar]
  • 13. Yu WL, Chuang YC, Walther‐Rasmussen J. Extended‐spectrum beta‐lactamases in Taiwan: Epidemiology, detection, treatment, and infection control. J Microbiol Immunol Infect 2006;39:264–277. [PubMed] [Google Scholar]
  • 14. Bonnet R. Growing group of extended‐spectrum beta‐lactamases: The CTX‐M enzymes. Antimicrob Agents Chemother 2004;48:1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Canton R, Coque TM. The CTX‐M beta‐lactamase pandemic. Curr Opin Microbiol 2006;9:466–475. [DOI] [PubMed] [Google Scholar]
  • 16. Lavollay M, Mamlouk K, Frank T, Akpabie A, Burghoffer B, Ben Redjeb S. Clonal dissemination of a CTX‐M‐15 β‐Lactamase‐producing Escherichia coli strain in the Paris area, Tunis, and Bangui. Antimicrob Agents Chemother 2006;50:2433–2438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Livermore DM, Woodford N. The β‐lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006;14:413–414. [DOI] [PubMed] [Google Scholar]
  • 18. Naas T, Lezzar A, Bentchouala C, Smati F, Scheftel JM, Monteil H. Multidrug‐resistant Salmonella enterica serotype Senftenberg isolates producing CTX‐M β‐lactamases from Constantine, Algeria. J Antimicrob Chemother 2005;56:439–440. [DOI] [PubMed] [Google Scholar]
  • 19. Messai Y, Benhassine B, Naim M, Paul G, Bakour R. Prevalence of betalactams resistance among Escherichia coli clinical isolates from a hospital in Algiers. Rev Esp Quimioter 2006;19:144–151. [PubMed] [Google Scholar]
  • 20. Ramdani‐Bouguessa N, Mendonça N, Leitão J, Ferreira E, Tazir M, Caniça M. CTX‐M‐3 and CTX‐M‐15 extended‐spectrum β‐lactamases in isolates of Escherichia coli from a hospital in Algiers, Algeria. J Clin Microbiol 2006;44:4584–4586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Touati A, Benallaoua S, Forte D, Madoux J, Brasme L, de Champs C. First report of CTX‐M‐15 and CTX‐M‐3 beta‐lactamases among clinical isolates of Enterobacteriaceae in Béjaia, Algeria. Int J Antimicrob Agents 2006;27:397–402. [DOI] [PubMed] [Google Scholar]
  • 22. Iabadene H, Messai Y, Ammari H, et al. Dissemination of ESBL and Qnr determinants in Enterobacter cloacae in Algeria. J Antimicrob Chemother 2008;62:133–136. [DOI] [PubMed] [Google Scholar]
  • 23. Mamlouk K, Boutiba‐Ben Boubaker I, Gautier V, et al. Emergence and outbreaks of CTX‐M β‐lactamase‐producing Escherichia coli and Klebsiella pneumoniae strains in a Tunisian hospital. J Clin Microbiol 2006;44:4049–4056. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES